Gilead Sciences recently announced positive results from the Phase 3 ASCENT-04/KEYNOTE-D19 study, highlighting significant benefits in treating metastatic triple-negative breast cancer. This ...

Besides Ascent-04, Gilead expects a readout by June from the phase 3 Ascent-03 trial pitting Trodelvy against chemo in first-line, PD-L1-negative metastatic TNBC. The Ascent-05 study is testing ...

Gilead Sciences and Sophia Forum, a London-based charity, have launched a campaign to improve HIV care and outreach for women in the U.K.—a group that, according to the partners, has long been ...

Gilead Sciences has reported positive topline data from the randomised Phase III ASCENT-04/KEYNOTE-D19 trial of Trodelvy (sacituzumab govitecan-hziy) and MSD’s Keytruda (pembrolizumab) combo in ...

April 21 (Reuters) - Gilead Sciences (GILD.O), opens new tab said on Monday a late-stage study showed that its drug Trodelvy used in combination with Merck's (MRK.N), opens new tab immunotherapy ...

Gilead Sciences GILD has been analyzed by 15 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The following table provides a quick overview of ...

You can reach Adam on Signal at stataf.54. Gilead Sciences said Monday that a combination of its cancer drug Trodelvy and Merck’s Keytruda delayed the growth of tumors in women with a less ...

Compared to the aggregate P/E ratio of 57.02 in the Biotechnology industry, Gilead Sciences Inc. has a higher P/E ratio of 277.66. Shareholders might be inclined to think that Gilead Sciences Inc ...

Though the trio successfully managed to infiltrate Jezebel and meet up with Janine (Madeline Brewer), whose help they need to destroy Gilead, it is not yet known if they managed to make it out ...

Gilead has an impeccable earnings track record so far. It beat earnings estimates in each of the last four quarters, delivering an average surprise of 19.47%. In the last reported quarter ...

In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against other cheap NASDAQ stocks. On April 10, Dan Ives, Head of Global Tech Research at Wedbush ...